top of page

Leveraging AI To Accelerate Precision Health For Longevity

People over 50 are the fastest growing demographic group worldwide. This creates both opportunities and challenges for the global economy and healthcare systems. The Longevity Industry, which provides products and services for those aged over 50 is becoming a multi-trillion-dollar industry. There are currently 260 companies, 250 investors, 10 non-profits, and 10 research labs in the Longevity Industry in the UK alone. In the next decade, Longevity policies enacted by governments, and changes in the financial industry will transform society. Achieving small but practical results in Longevity distributed at scale will have enormous and multiplicative effects on society. Extending the functional lifespan of humans by just one year will decrease suffering for tens of millions of people and will improve the quality of life for billions of people.

Longevity AI Consortium at King’s College London

Despite having more potential to increase healthy Longevity in the short term than any other sector, AI for Longevity is an underrepresented sector in the Longevity Industry. AI holds enormous potential to rapidly accelerate the implementation of longevity research and development. To address this, Ageing Research at King's (ARK) in collaboration with the Biogerontology Research Foundation, Deep Knowledge Ventures and other organizations have established the Longevity AI Consortium at King’s College London. The Consortium will use King's world-leading advances in genetics, AI and aging research to develop advanced personalized consumer and patient care.

The Consortium will help accelerate advances in Longevity using a unique academic-industry focus on preventive and personalized physical, mental and financial health. The establishment of the AI Longevity Consortium and AI Longevity Accelerator at King’s College has the potential to help make the UK the world’s leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit people all around the world.

Over the next few years, the Longevity AI Consortium plans to expand to include centers in Switzerland, Israel, Singapore and the United States through a £7 million commitment from Deep Knowledge Ventures. This collaborative effort involves sophisticated methods for translating advanced AI for Longevity solutions, along with the development of advanced frameworks and technologies including novel applications of life data for insurance companies, pension funds, healthcare companies, and government bodies. These new technologies and instruments at the forefront of the rising Longevity Financial Industry provide practical applications of preventive medicine and precision health.

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. This represents a paradigm shift from treatment to prevention and a new frontier - from precision medicine to precision health, enabling the UK to become the leading global hub for the application of AI to Longevity and Precision Health. The Longevity AI Consortium plans to dedicate resources to R&D in other niches where the science is ahead of the funding: e.g. microbiome diagnostics and therapeutics, recent advancements and innovations in advanced cosmetics in particular. The Consortium aims to identify novel longevity and healthy ageing biomarkers, accelerate diagnosis of age-related health decline, develop personalised physical, mental and financial health to better implement and promote effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure and financial planning.

The Longevity AI Consortium will use sophisticated and multidimensional analytical frameworks developed by Aging Analytics Agency to perform industry benchmarking in precision health and personalized preventive medicine clinics in order to construct the ideal diagnostic, prognostic and therapeutic pipeline using the most advanced market-ready methods and technologies. The Consortium will develop a comprehensive cloud computing platform to enable the development of “minimum viable” and “most comprehensive” panels of biomarkers of aging, creating an ecosystem that incentivizes the participation of doctors, clinics, data providers, AI companies and corporate partners, and which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing as a framework for the extension of national Healthy Longevity in the UK.

King’s College London is the logical choice of location for the first Longevity AI Consortium, due to their unique combination of resources, departments and technologies for both AI and Longevity. King’s is also an ideal location for the AI Consortium because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration. The AI Longevity Consortium is currently designing a complementary AI Consortium for Financial Wellness which will utilize financial and behavioural data to develop products and services to enable UK citizens to maintain financial stability, social activity and psychological well-being across extended periods of Healthy Longevity. 

Currently there are only three centers in the world actively working to apply AI to precision health for healthy Longevity. These include the US based Buck Institute for Research on Aging, US based Y Combinator, and the US based AI Precision Health Institute (AI-PHI) at the University of Hawaii Cancer Center. Only the AI-PHI has actually succeeded in practice. Now that the Longevity AI Consortium has been established at King’s College London, the UK can immediately leverage its existing resources, including its very well-developed AI industry and its reputation for extremely strong industry, academic, and governmental cooperative initiatives, to become the number one global hub for the application of AI to Longevity and Precision Health.

There are currently four major AI Centers for Healthcare in major industry, academic and metropolitan hubs in the UK, but none of them have a specific focus on Longevity, precision health and preventive medicine. While these centres serve as a precedent and proof-of-concept for the viability of an AI Centre for Longevity, they do not adequately address the need for a leading AI for Longevity R&D nexus within the UK capable of developing leading solutions, products and services that leverage the power of AI to implement practical, real-world product, services and solutions to extend citizens’ Healthy Longevity.

2020 and Beyond

In 2020, following the completion of several key development milestones, the Longevity AI Consortium plans to launch an AI Longevity Accelerator Program that will serve as a much-needed bridge between startups focusing on AI for Longevity research and drug development and major UK investors. While the UK’s AI and Longevity industry ecosystems are very developed individually, the number of longevity startups utilizing AI in a major way for their internal R&D is comparatively small. The potential impact presented by the synergy of these two sectors is huge. The UK government has heavily prioritized the separate sectors of AI and Longevity, including both sectors in the top 4 Industrial Strategy Grand Challenges. However, by uniting the AI and Longevity verticals in unique and convergent ways the UK could leverage the nation’s strengths in these industries to their maximum potential.

Longevity companies that prove capable of achieving tangible results may become the next Googles, and investment firms that invest in those companies may become the SoftBanks and Vision Funds of tomorrow. AI holds enormous potential to rapidly accelerate the implementation of Longevity research and development. The establishment of the AI Longevity Consortium at King’s College has the potential to make the UK the world’s leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit billions of people all around the world.

This article was published in Forbes on November 24, 2019.

Subscribe and Comment

We're interested in your feedback. Please leave your comments in the comments section. Please click the subscribe button at the top of the page to subscribe to this Global Longevity Newsletter.

This article was written by Margaretta Colangelo and Dmitry Kaminskiy.

Dmitry Kaminskiy is General Partner of Deep Knowledge Ventures, Founding Partner of Longevity.Capital, Founder of Aging Analytics Agency, Founder of Deep Knowledge Analytics, Founder of Deep Knowledge Ventures, and Founder of Longevity.Capital. He is the Head of International Development of the Secretariat for the UK All-Party Parliamentary Group for Longevity and Managing Trustee of the Biogerontology Research Foundation. Dmitry is based in London.  

Margaretta Colangelo is Co-founder and Managing Partner of Deep Knowledge Ventures and Longevity Capital. She is Co-founder of Aging Analytics Agency, and Co-founder of Deep Knowledge Analytics. Margaretta serves on the Advisory Board of the AI Precision Health Institute at the University of Hawai‘i Cancer Center. Margaretta is based in San Francisco.

Deep Knowledge Group is a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, media, analytics and more. Its subsidiaries and associated organisations include Deep Knowledge Ventures, Longevity.Capital, AI-Pharma.Capital, Longevity FinTech Company, Deep Knowledge Analytics, Aging Analytics Agency, Biogerontology Research Foundation, Longevity Swiss Foundation, Longevity International UK - Secretariat for the UK All-Party Parliamentary on Longevity, and AI-Longevity Consortium at King’s College London.

Deep Knowledge Ventures is a leading investment fund focused on the synergetic convergence of DeepTech, frontier technologies and technological megatrends, known for its use of sophisticated analytical system for investment target identification and due-diligence. Major investment sectors include AI, Precision Medicine, Longevity, Blockchain and InvestTech. Deep Knowledge Ventures' Pharma-AI Index Hedge Fund combines the profitability of venture funds with the liquidity of hedge funds significantly de-risking the interests of LP’s and simultaneously providing the best and most promising AI companies with a relevant amount of investment.

14 visualizzazioni0 commenti

Post recenti

Mostra tutti


bottom of page